Results 31 to 40 of about 967,967 (261)

Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke [PDF]

open access: yes, 2012
Genetic factors have been implicated in stroke risk, but few replicated associations have been reported. We conducted a genome-wide association study (GWAS) for ischemic stroke and its subtypes in 3,548 affected individuals and 5,972 controls, all of ...
Furie, K.   +452 more
core   +2 more sources

Differences in the evolution of the ischemic penumbra in stroke-prone spontaneously hypertensive and Wistar-Kyoto rats [PDF]

open access: yes, 2009
<p><b>Background and Purpose:</b> Stroke-prone spontaneously hypertensive rats (SHRSP) are a highly pertinent stroke model with increased sensitivity to focal ischemia compared with the normotensive reference strain (Wistar-Kyoto rats ...
Dominiczak, Anna F.   +5 more
core   +1 more source

Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset [PDF]

open access: yes, 2010
<p><b>Background and Purpose:</b> Antiplatelets (APs) may increase the risk of symptomatic intracerebral hemorrhage (ICH) following intravenous thrombolysis after ischemic stroke.</p> <p><b>Methods:</b> We ...
Wahlgren, N.   +32 more
core   +1 more source

HDAC4 in ischemic stroke: mechanisms and therapeutic potential

open access: yesClinical Epigenetics, 2018
Stroke is one of the leading causes of death and disability worldwide, and the majority of the cases are ischemic stroke. However, it still lacks effective treatment except for thrombolytic therapy in an extremely narrow time window.
Qingsheng Kong   +5 more
doaj   +1 more source

Dose escalation of desmoteplase for acute ischemic stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset [PDF]

open access: yes, 2006
<p><b>Background and Purpose:</b> Desmoteplase is a novel plasminogen activator with favorable features in vitro compared with available agents.
Lees, K.R.   +9 more
core   +1 more source

A study on structural imaging changes and serum neurofilament light chain (NfL) levels in individuals with white matter hyperintensities, combining imaging techniques with biomarker analysis

open access: yesIBRO Neuroscience Reports
Objective: To elucidate the association between serum neurofilament light chain (NfL) levels and structural brain alterations in individuals exhibiting white matter hyperintensities (WMHs), as well as to investigate the potential utility of serum NfL as ...
Meini Wu   +8 more
doaj   +1 more source

Microbiome and ischemic stroke: A systematic review.

open access: yesPLoS ONE, 2021
BackgroundIschemic stroke is one of the non-communicable diseases that contribute to the significant number of deaths worldwide. However, the relationship between microbiome and ischemic stroke remained unknown.
Yee Teng Lee   +2 more
doaj   +1 more source

Ischemic Stroke During the Pandemic in a Secondary Care Hospital: COVID-19 and Its Collateral Effects

open access: yesBatı Karadeniz Tıp Dergisi, 2023
Aim: Ischemic stroke is among the leading causes of death and disability. Although recent studies haveshown a possible relationship between COVID-19 and ischemic stroke, the effect of the pandemic period,which may be another factor in the increase of ...
Elif Uygur Kucukseymen   +2 more
doaj   +1 more source

Relationship between hyperacute blood pressure and outcome after ischemic stroke: data from the VISTA Collaboration [PDF]

open access: yes, 2009
Background and Purpose—High blood pressure (BP) is associated independently with poor outcome after acute ischemic stroke, although in most analyses “baseline” BP was measured 24 hours or more postictus, and not during the hyperacute period.
Bath, P.M.B.   +12 more
core   +1 more source

The Desmoteplase In Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase [PDF]

open access: yes, 2005
<p><b>Background and Purpose:</b> Most acute ischemic stroke patients arrive after the 3-hour time window for recombinant tissue plasminogen activator (rtPA) administration.
Fischer, M.   +21 more
core   +1 more source

Home - About - Disclaimer - Privacy